Hung The Huynh

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1363838/publications.pdf

Version: 2024-02-01

46 papers	2,222 citations	257101 24 h-index	223531 46 g-index
47 all docs	47 docs citations	47 times ranked	3485 citing authors

#	Article	IF	Citations
1	Ribociclib enhances infigratinibâ€induced cancer cell differentiation and delays resistance in FGFRâ€driven hepatocellular carcinoma. Liver International, 2021, 41, 608-620.	1.9	11
2	Dynamic Contrast-Enhanced Magnetic Resonance Imaging as Imaging Biomarker for Vascular Normalization Effect of Infigratinib in High-FGFR-Expressing Hepatocellular Carcinoma Xenografts. Molecular Imaging and Biology, 2021, 23, 70-83.	1.3	1
3	Upregulation of the ErbB family by EZH2 in hepatocellular carcinoma confers resistance to FGFR inhibitor. Journal of Cancer Research and Clinical Oncology, 2021, 147, 2955-2968.	1.2	6
4	Targeted inhibition of FGF19/FGFR cascade improves antitumor immunity and response rate in hepatocellular carcinoma. Hepatology International, 2021, 15, 1236-1246.	1.9	6
5	FGF401 and vinorelbine synergistically mediate antitumor activity and vascular normalization in FGF19-dependent hepatocellular carcinoma. Experimental and Molecular Medicine, 2020, 52, 1857-1868.	3.2	13
6	Bevacizumab Augments the Antitumor Efficacy of Infigratinib in Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2020, 21, 9405.	1.8	9
7	Vinorelbine Augments Radiotherapy in Hepatocellular Carcinoma. Cancers, 2020, 12, 872.	1.7	6
8	Resistance to allosteric SHP2 inhibition in FGFR-driven cancers through rapid feedback activation of FGFR. Oncotarget, 2020, 11, 265-281.	0.8	27
9	Sorafenib/MEK inhibitor combination inhibits tumor growth and the Wnt/Î²â€catenin pathway in xenograft models of hepatocellular carcinoma. International Journal of Oncology, 2019, 54, 1123-1133.	1.4	20
10	Infigratinib Mediates Vascular Normalization, Impairs Metastasis, and Improves Chemotherapy in Hepatocellular Carcinoma. Hepatology, 2019, 69, 943-958.	3.6	48
11	Action of YM155 on clear cell renal cell carcinoma does not depend on survivin expression levels. PLoS ONE, 2017, 12, e0178168.	1.1	12
12	Microarray profiling shows distinct differences between primary tumors and commonly used preclinical models in hepatocellular carcinoma. BMC Cancer, 2015, 15, 828.	1.1	13
13	Antitumor activity of the multikinase inhibitor regorafenib in patient-derived xenograft models of gastric cancer. Journal of Experimental and Clinical Cancer Research, 2015, 34, 132.	3.5	37
14	Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus. Molecular Cancer Therapeutics, 2015, 14, 1224-1235.	1.9	74
15	FGFR-Mediated Reactivation of MAPK Signaling Attenuates Antitumor Effects of Imatinib in Gastrointestinal Stromal Tumors. Cancer Discovery, 2015, 5, 438-451.	7.7	83
16	Paracrine Factors of Human Fetal MSCs Inhibit Liver Cancer Growth Through Reduced Activation of IGF-1R/PI3K/Akt Signaling. Molecular Therapy, 2015, 23, 746-756.	3.7	72
17	MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma. Molecular Cancer Therapeutics, 2015, 14, 1750-1760.	1.9	46
18	Assessment of tumor necrotic fraction by dynamic contrastâ€enhanced MRI: a preclinical study of human tumor xenografts with histopathologic correlation. NMR in Biomedicine, 2014, 27, 486-494.	1.6	10

#	Article	IF	Citations
19	Preclinical Evaluation of Transcriptional Targeting Strategy for Human Hepatocellular Carcinoma in an Orthotopic Xenograft Mouse Model. Molecular Cancer Therapeutics, 2013, 12, 1651-1664.	1.9	9
20	Combination of the ERK inhibitor AZD6244 and low-dose sorafenib in a xenograft model of human renal cell carcinoma. International Journal of Oncology, 2012, 41, 712-720.	1.4	26
21	Dovitinib demonstrates antitumor and antimetastatic activities in xenograft models of hepatocellular carcinoma. Journal of Hepatology, 2012, 56, 595-601.	1.8	50
22	Foretinib demonstrates anti-tumor activity and improves overall survival in preclinical models of hepatocellular carcinoma. Angiogenesis, 2012, 15, 59-70.	3.7	53
23	Targeting Receptor Tyrosine Kinase Pathways in Hepatocellular Carcinoma. Anti-Cancer Agents in Medicinal Chemistry, 2011, 11, 560-575.	0.9	24
24	Molecularly targeted therapy in hepatocellular carcinoma. Biochemical Pharmacology, 2010, 80, 550-560.	2.0	110
25	AZD6244 (ARRYâ€142886) enhances the antitumor activity of rapamycin in mouse models of human hepatocellular carcinoma. Cancer, 2010, 116, 1315-1325.	2.0	39
26	Hybrid herpes simplex virus/Epsteinâ€"Barr virus amplicon viral vectors confer enhanced transgene expression in primary human tumors and human bone marrowâ€derived mesenchymal stem cells. Journal of Gene Medicine, 2010, 12, 848-858.	1.4	9
27	Tyrosine kinase inhibitors to treat liver cancer. Expert Opinion on Emerging Drugs, 2010, 15, 13-26.	1.0	20
28	AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC). Journal of Hepatology, 2010, 52, 79-87.	1.8	88
29	Sorafenib induces growth suppression in mouse models of gastrointestinal stromal tumor. Molecular Cancer Therapeutics, 2009, 8, 152-159.	1.9	50
30	AZD6244 (ARRY-142886) enhances the therapeutic efficacy of sorafenib in mouse models of gastric cancer. Molecular Cancer Therapeutics, 2009, 8, 2537-2545.	1.9	30
31	RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma. Journal of Cellular and Molecular Medicine, 2009, 13, 1371-1380.	1.6	128
32	Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. Journal of Cellular and Molecular Medicine, 2009, 13, 2673-2683.	1.6	118
33	Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. Journal of Hepatology, 2008, 49, 52-60.	1.8	84
34	An Epstein-Barr virus positive natural killer lymphoma xenograft derived for drug testing. Leukemia and Lymphoma, 2008, 49, 1161-1167.	0.6	11
35	Brivanib Alaninate, a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Tyrosine Kinases, Induces Growth Inhibition in Mouse Models of Human Hepatocellular Carcinoma. Clinical Cancer Research, 2008, 14, 6146-6153.	3.2	213
36	Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma. Molecular Cancer Therapeutics, 2007, 6, 138-146.	1.9	139

#	Article	IF	Citations
37	AZD6244 and doxorubicin induce growth suppression and apoptosis in mouse models of hepatocellular carcinoma. Molecular Cancer Therapeutics, 2007, 6, 2468-2476.	1.9	42
38	Bevacizumab and rapamycin inhibit tumor growth in peritoneal model of human ovarian cancer. Molecular Cancer Therapeutics, 2007, 6, 2959-2966.	1.9	47
39	Xenografts of Human Hepatocellular Carcinoma: A Useful Model for Testing Drugs. Clinical Cancer Research, 2006, 12, 4306-4314.	3.2	98
40	Overexpression of tumour suppressor retinoblastoma 2 protein (pRb2/p130) in hepatocellular carcinoma. Carcinogenesis, 2004, 25, 1485-1494.	1.3	24
41	2-Chloroethyl-3-sarcosinamide-1-nitrosourea (SarCNU) inhibits prostate carcinoma cell growth via p53-dependent and p53-independent pathways. Cancer, 2004, 101, 2881-2891.	2.0	5
42	Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: Its role in tumor progression and apoptosis. BMC Gastroenterology, 2003, 3, 19.	0.8	244
43	Inhibition of ErbB-2 and ErbB-3 expression by quercetin prevents transforming growth factor alpha (TGF-alpha)- and epidermal growth factor (EGF)-induced human PC-3 prostate cancer cell proliferation. International Journal of Oncology, 2003, 23, 821-9.	1.4	19
44	A possible role for insulin-like growth factor-binding protein-3 autocrine/paracrine loops in controlling hepatocellular carcinoma cell proliferation. Cell Growth & Differentiation: the Molecular Biology Journal of the American Association for Cancer Research, 2002, 13, 115-22.	0.8	26
45	Induction of apoptosis in rat ventral prostate by finasteride is associated with alteration in MAP kinase pathways and Bcl-2 related family of proteins. International Journal of Oncology, 2002, 20, 1297-303.	1.4	11
46	Post-transcriptional and post-translational regulation of insulin-like growth factor binding protein-3 and -4 by insulin-like growth factor-I in uterine myometrial cells. Growth Hormone and IGF Research, 2000, 10, 20-27.	0.5	11